Rethinking Treatment Goals in Psoriasis: Leveraging IL-17 Inhibitors to Move Beyond Skin Clearance Toward PsA Prevention

In this opening segment, the experts introduce this series focused on rethinking treatment goals in psoriasis. The discussion begins with an overview of the strong pathophysiologic link between psoriasis and psoriatic arthritis (PsA). The panelists explain that both conditions share an IL-23/Th17 inflammatory pathway, where activation of Th17 cells leads to cytokine release—such as IL-17A, IL-17F, and IL-22—driving inflammation in both skin and joints. This common mechanism helps explain why approximately one-third of patients with psoriasis eventually develop PsA. The experts emphasize that recognizing this overlap supports the need for therapeutic strategies that target shared cytokines early in the disease course. By addressing systemic inflammation before joint damage occurs, clinicians may be able to modify disease progression and improve long-term outcomes for patients with psoriatic disease.

In this discussion, the panelists explore the identification of risk factors and the broader impact of psoriatic disease. The experts explain that certain clinical features—such as scalp and nail involvement, higher body surface area, and disease severity—are associated with an increased likelihood of developing psoriatic arthritis (PsA). They also note that modifiable factors like obesity, smoking, and metabolic syndrome further contribute to this risk. While genetics play a role, the experts emphasize the importance of addressing lifestyle factors and systemic inflammation early. The conversation highlights that psoriasis should be recognized as a systemic disease rather than one limited to the skin. By identifying high-risk patients and initiating systemic therapy sooner, clinicians can better manage inflammation, improve quality of life, and potentially reduce PsA progression. The panel underscores the importance of patient education and multidisciplinary care to optimize outcomes.

In this segment, the panelists discuss how dermatologists and rheumatologists can collaborate more effectively to detect psoriatic arthritis (PsA) early. The experts explain that dermatologists are often the first to encounter patients with psoriasis and play a crucial role in screening for musculoskeletal symptoms such as joint pain, stiffness, or enthesitis. They highlight practical tools like the PEST questionnaire, which helps identify patients who may require rheumatology referral. The discussion emphasizes that even subtle or subclinical symptoms should prompt consideration of systemic therapy or closer monitoring. The panelists note that clear communication between specialties improves early detection, enabling timely intervention before irreversible joint damage occurs. They advocate for dermatologists to incorporate quick joint assessments and patient education into routine visits, reinforcing the value of a collaborative, multidisciplinary approach to comprehensive psoriatic disease management.

In this episode, the panelists explore the concept of disease interception and how early intervention may address unmet needs in psoriatic arthritis (PsA). The experts discuss emerging evidence suggesting that PsA can be reframed as a preventable disease when treated before clinical joint symptoms appear. They note that subclinical inflammation, detectable through imaging such as Doppler ultrasound or MRI, often exists in patients with psoriasis, particularly at the entheses. This early immune activation highlights the potential to intervene upstream by targeting shared cytokine pathways, such as IL-23 and IL-17. The panel emphasizes that dermatologists, often the first point of contact, play a pivotal role in identifying high-risk patients—those with scalp or nail involvement—and considering systemic therapy even in the absence of joint symptoms. Current biologic treatments that address both skin and joint inflammation may help modify disease progression and prevent irreversible PsA-related damage.

In this discussion, the panelists examine current evidence supporting early systemic treatment in psoriasis to help prevent psoriatic arthritis (PsA). The experts reference retrospective and observational studies suggesting that biologic therapies—particularly IL-17 and IL-23 inhibitors—may reduce the incidence of PsA development among patients with psoriasis. While acknowledging limitations in available data, such as the lack of prospective randomized trials, the panelists agree that existing evidence is meaningful and should inform proactive management. They stress that early initiation of systemic therapy can address the shared inflammatory pathways of skin and joint disease, potentially modifying disease progression before irreversible joint damage occurs. The experts highlight the importance of shifting from reactive to preventive care, emphasizing that treating psoriasis systemically and earlier in its course could close the current gap between achieving complete skin clearance and preventing long-term musculoskeletal complications.

In this episode, the panelists focus on the IL-23 and IL-17 pathways and their influence on inflammation control and psoriatic arthritis (PsA) prevention. The experts explain that IL-23 sits at the top of the inflammatory cascade, driving Th17 cell activation and downstream cytokine release. They note that inhibiting IL-23 can lead to long-term immunologic remission and possibly modify PsA progression, given its infrequent dosing and favorable safety profile. The discussion compares IL-23 and IL-17 inhibition, highlighting that while IL-23 blockade targets disease upstream, IL-17 acts as the “enforcer” cytokine driving local joint and skin inflammation. The panelists review emerging data showing that dual inhibition of IL-17A and IL-17F, as achieved with newer biologics, may provide more robust and durable skin clearance than targeting IL-17A alone. They conclude that deeper inflammation control through these pathways could reduce PsA risk and sustain long-term disease remission.

In this episode, the panelists share clinical perspectives on positioning IL-17 inhibitors within psoriasis treatment. The experts discuss that among available biologic options, IL-17 inhibitors provide rapid and durable skin clearance, making them an important choice for patients with moderate to severe psoriasis. They highlight the significance of dual IL-17A and IL-17F inhibition, noting that it offers greater depth of response compared to targeting IL-17A alone. When selecting therapy, the panel emphasizes tailoring treatment to individual patient factors—such as nail involvement, disease burden, or potential psoriatic arthritis risk. They also consider head-to-head data showing that IL-17 inhibitors can achieve superior outcomes compared with other classes, including IL-23 inhibitors, in certain patient groups. The experts conclude that positioning IL-17 inhibitors early in the treatment algorithm may not only improve skin outcomes but also support prevention of disease progression.

The panelists review EADV 2025 data evaluating whether bimekizumab may help prevent PsA development in patients with psoriasis only. The study followed psoriasis patients prospectively and stratified risk using clinical factors and a patient questionnaire (PASE), treating scores <47 as low risk and ≥47 as high risk. Among patients with >1 risk factor treated with bimekizumab, over 96% maintained PASE scores <47 on longitudinal follow-up—used here as a patient-reported surrogate for not developing PsA symptoms (noting the limitation of no comparator arm). These findings align with real-world practice that prioritizes identifying high-risk patients and monitoring symptom trajectories over time. Overall, the experts interpret the stratified results as supportive—though preliminary—evidence that sustained IL-17A/F blockade may reduce transition to PsA in higher-risk psoriasis populations, while emphasizing the need for prospective, comparative data.

In this episode, the panelists discuss long-term IL-17 data and real-world evidence on preventing psoriatic arthritis (PsA) in patients with psoriasis. They highlight results from the five-year secukinumab study presented at ACR Convergence 2025, which showed that 97.9% of psoriasis patients treated with secukinumab did not develop PsA over the study period. The experts view this as compelling evidence supporting the disease-modifying potential of IL-17 inhibition. They also reference real-world data which compared PsA incidence across biologic classes and found that IL-17 and IL-23 inhibitors were associated with a lower PsA risk than TNF inhibitors or methotrexate. The panelists emphasize that IL-17 inhibitors not only achieve durable skin clearance but also offer a favorable safety profile and reduced need for lab monitoring. Overall, they interpret these findings as reinforcing the role of targeted IL-17 blockade in preventing PsA progression in high-risk psoriasis patients.

In this episode, the panelists focus on evaluating the safety profile of IL-17 inhibitors in psoriatic disease. The experts explain that IL-17 therapies are generally well tolerated and offer a favorable safety profile compared with older systemic agents like TNF inhibitors and methotrexate, which require frequent lab monitoring. They note that while all IL-17 inhibitors share certain class effects, the most commonly observed adverse event is mucosal or oral candidiasis, which is typically mild, manageable, and tends to decrease over time. The panelists emphasize careful patient selection, avoiding IL-17 inhibitors in individuals with a history of inflammatory bowel disease (IBD), given the risk of exacerbation. They briefly discuss safety observations from dual IL-17A and IL-17F blockade, noting reports of liver enzyme elevation and mood changes, though these lack strong mechanistic evidence. Overall, the experts conclude that IL-17 inhibitors provide a safe, targeted, and effective option for long-term psoriasis and PsA management.

In this episode, the panelists explore how to balance the benefits and risks of initiating systemic therapy early in patients with psoriasis who do not yet have joint involvement. The experts discuss that starting treatment is more straightforward in patients with moderate to severe plaque psoriasis, where strong clinical data support systemic use. However, the decision becomes more nuanced for those with limited disease. In such cases, factors like lesion location (nail, scalp, or other special sites), previous treatment failures, and patient motivation play an important role. The panel emphasizes the importance of shared decision-making, considering both the clinical picture and patient preferences. They note that even in mild cases, residual skin inflammation reflects ongoing systemic activity, and early therapy may still provide long-term benefits. The experts conclude that treatment should address both disease burden and patient quality of life, while maintaining a risk–benefit balance.

In this episode, the panelists address key barriers to adopting a preventive treatment approach in psoriatic disease. The experts agree that insurance approval and prior authorization processes remain the most significant obstacles to initiating early systemic therapy. They describe the administrative challenges involved, including formulary restrictions, step therapy requirements, and the extensive time needed to secure coverage. Many dermatology practices have responded by employing biologic coordinators to handle these complex approval procedures, allowing clinicians to focus on patient care. The panelists also discuss patient-driven barriers, such as direct-to-consumer advertising that influences medication requests, and cases where patients seek drugs inappropriate for their specific disease subtype. Through these examples, the experts highlight how both system-level hurdles and patient perceptions can delay optimal therapy. They emphasize the importance of advocacy, education, and workflow support to overcome these barriers and enable earlier, prevention-focused management of psoriatic disease.

In this episode, the panelists discuss how the definition of treatment success and remission in psoriasis has evolved. Historically, achieving PASI 75 was considered adequate, but the experts explain that PASI 100, or complete skin clearance, is now the preferred benchmark. They reference the National Psoriasis Foundation’s 2025 consensus statement, which defines remission as maintaining ≤1% body surface area involvement for at least six months and a DLQI score of 0 or 1, indicating no impact on quality of life. The panelists emphasize that complete skin clearance reflects a deeper suppression of systemic inflammation and may reduce the risk of psoriatic arthritis. They also highlight that visible clearance serves as a practical measure in the absence of validated biomarkers. With current systemic therapies making PASI 100 an attainable goal, the experts agree that striving for sustained remission represents both clinical success and improved long-term outcomes.

In this episode, the panelists review long-term efficacy data for bimekizumab presented at EADV 2025, focusing on sustained remission and disease control in psoriasis. The experts highlight that approximately 49% of patients maintained complete skin clearance (PASI 100) from month 4 through year 4, with about 72% sustaining complete or near-complete clearance over the same period. They interpret these findings as strong evidence of durability and depth of response, underscoring bimekizumab’s ability to maintain remission over years rather than months. The discussion also includes nail outcomes, with nearly 80% of patients maintaining NAPSI 0, indicating resolution of nail involvement—an important factor given its association with psoriatic arthritis risk. The panelists emphasize that by achieving and maintaining high levels of clearance in both skin and nails, bimekizumab may help interrupt the inflammatory progression that leads to PsA, reinforcing its role in comprehensive disease control.